NCT00946491已完成1 期
An Open-Label, Single-Dose, Crossover Study to Determine the Bioequivalency of Generic Haloperidol Tablets vs. Haldol in Normal Volunteers.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sandoz
- 入组人数
- 30
- 主要终点
- Bioequivalence based on AUC and Cmax
研究概览
简要总结
To demonstrate the relative bioequivalency of generic Haloperidol tablets versus Haldol in normal volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
排除标准
- •Positive test results for HIV or hepatitis B or C.
- •Treatment for drug or alcohol dependence.
研究组 & 干预措施
1
Experimental
Haloperidol 10 mg Tablets (Cord Laboratories)
干预措施: Haloperidol 10 mg Tablets (Cord Laboratories) (Drug)
2
Active Comparator
Haldol 10 mg Tablets (McNeil Pharmaceuticals)
干预措施: Haldol 10 mg Tablets (McNeil Pharmaceuticals) (Drug)
结局指标
主要结局
Bioequivalence based on AUC and Cmax
时间窗: 17 days
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and VacavilleSchizophreniaNCT00790777Johnson & Johnson Pharmaceutical Research & Development, L.L.C.72
已完成
1 期
Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting ConditionsBioequivalenceNCT04411940Cycle Pharmaceuticals Ltd.32
已完成
1 期
Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed ConditionsBioequivalenceNCT04411953Cycle Pharmaceuticals Ltd.32
终止
3 期
Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced CancerNauseaNeoplasmsNCT00124930Alberta Health services80
已完成
1 期
Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution)HealthyNCT05716763Unither Pharmaceuticals, France24